<DOC>
	<DOC>NCT02082691</DOC>
	<brief_summary>Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.</brief_summary>
	<brief_title>Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>History of hepatocellular carcinoma Participation in prior research study where G202 was administered Tolerance of G202 treatment Demonstration of stable disease Disease progression Occurrence of unacceptable toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>G-202</keyword>
	<keyword>Hepatocellular</keyword>
</DOC>